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Background: RA flares are common and disabling. They are described in terms of worsening inflammation but
pain and inflammation are often discordant. To inform treatment decisions, we investigated whether inflammatory
and pain flares are discrete entities.
Methods: People from the Early RA Network (ERAN) cohort were assessed annually up to 11 years after
presentation (n = 719, 3703 person-years of follow up). Flare events were defined in 2 different ways that were
analysed in parallel; DAS28 or Pain Flares. DAS28 Flares satisfied OMERACT flare criteria of increases in DAS28 since
the previous assessment (≥1.2 points if active RA or ≥ 0.6 points if inactive RA). A ≥ 4.8-point worsening of SF36-
Bodily Pain score defined Pain Flares. The first documented episode of each of DAS28 and Pain Flare in each
person was analysed. Subgroups within DAS28 and Pain Flares were determined using Latent Class Analysis. Clinical
course was compared between flare subgroups.
Results: DAS28 (45%) and Pain Flares (52%) were each common but usually discordant, with 60% of participants in
DAS28 Flare not concurrently in Pain Flare, and 64% of those in Pain Flare not concurrently in DAS28 Flare. Three
discrete DAS28 Flare subgroups were identified. One was characterised by increases in tender/swollen joint counts
(14.4%), a second by increases in symptoms (13.1%), and a third displayed lower flare severity (72.5%). Two discrete
Pain Flare subgroups were identified. One occurred following low disease activity and symptoms (88.6%), and the
other occurred on the background of ongoing active disease and pain (11.4%). Despite the observed differences
between DAS28 and Pain Flares, each was associated with increased disability which persisted beyond the flare
episode.
Conclusion: Flares are both common and heterogeneous in people with RA. Furthermore our findings indicate
that for some patients there is a discordance between inflammation and pain in flare events. This discrete flare
subgroups might reflect different underlying inflammation and pain mechanisms. Treatments addressing different
mechanisms might be required to reduce persistent disability after DAS28 and Pain Flares.
Keywords: Early rheumatoid arthritis, Flares, Inflammation, Pain, Disability© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: Dan.mcwilliams@nottingham.ac.uk
1Pain Centre Versus Arthritis, University of Nottingham, Clinical Sciences
Building, City Hospital, Nottingham NG5 1PB, UK
2Division of ROD, University of Nottingham, Clinical Sciences Building, City
Hospital, Nottingham NG5 1PB, UK
Full list of author information is available at the end of the article
McWilliams et al. BMC Rheumatology            (2019) 3:49 Page 2 of 9Background
Flare events are a common experience for people with
chronic conditions, including those with rheumatoid
arthritis (RA). RA flares are often described by reference
to joint swelling, pain and fatigue, and interpreted as de-
teriorations in inflammation [1]. RA flare has been de-
fined as ‘a cluster of symptoms of sufficient duration and
intensity that cannot be self-managed by the patient and
require initiation, change or increase in therapy’ [2]. The
OMERACT initiative classified RA flare based upon in-
creases in the 28 joint disease activity score, DAS28 [3].
DAS28 is widely used in clinics, has validity for treat-
ment targets and shaping long-term outcomes [4]. These
DAS28-based flare criteria exceed 70% specificity and
sensitivity, compared with the judgement of the patient
[3]. They also showed sensitivity of 88–100%, and speci-
ficity of 57–65% for detecting investigator-defined flares
and after biologic discontinuation in 1 clinical trial [5].
There is evidence that flares contribute to worsening
cardiovascular morbidity, joint damage and other long-
term outcomes [6]. Fear of flares might induce wide-
ranging behavioural modifications, including retreat
from social life and reductions in physical activities over
long periods of time [7]. RA flares are commonly treated
with anti-inflammatory glucocorticosteroids and changes
to disease modifying anti-rheumatic drugs (DMARDs).
Increased pain is a common feature of RA flares. Pain
in RA might be driven by inflammatory disease activity,
but might also result from other mechanisms including
central sensitisation. Diverse pain mechanisms lead to
discordance between symptom report, physician report
and inflammatory parameters [8, 9]. Non-inflammatory
musculoskeletal pain can also be subject to periodic in-
creases in severity, for example in osteoarthritis [10] or
fibromyalgia [11]. Not all flares are associated with no-
ticeable joint swelling [7, 12], and flare severity in RA
might not necessarily reflect the degree of increase in in-
flammatory disease activity. Misinterpretation of RA
flares as indicative of uncontrolled inflammatory disease
could lead patients to be exposed to risks from interven-
tions which are either unnecessary or ineffective, and
might be a barrier to more effective management
options.
We hypothesised that amongst people who are ex-
periencing RA flares, discrete groups might be identi-
fied with increased inflammatory disease activity or
activation of non-inflammatory pain mechanisms. We
explored two types of flare that might require dis-
tinct, personalised, treatment; DAS28 Flares and Pain
Flares. We investigated, using Latent Class Analysis
(LCA) [13], possible heterogeneity within DAS28 and
Pain Flares, and report sequelae of discrete flare sub-
groups in terms of the key RA outcomes of DAS28,
pain and disability.Methods
Patients
Data were from the Early RA Network (ERAN), an in-
ception cohort recruited from 2002 to 2013 and followed
up until study end in 2013 [14]. Data in the ERAN study
were collected from 22 outpatient rheumatology centres
in UK and Ireland. All participants gave signed, in-
formed consent to participate in line with the Declar-
ation of Helsinki. The ERAN study was approved by
Trent Research Ethics Committee (reference 01/4/047).
Recruitment was at the first diagnosis of RA by a
rheumatologist, and follow up visits were at 3–6 months
and then annually after baseline. The eligible population
for this study were people who had 2 consecutive
DAS28-ESR scores and 2 consecutive SF36-Bodily Pain
measures reported during baseline and follow up. The
consecutive DAS28-ESR and SF36-Bodily Pain values
could be taken from any eligible time points. To avoid
multiple counting, only one DAS28 and one Pain Flare
episode was investigated per patient (the first docu-
mented flare of each type after recruitment to the co-
hort). The eligible population for this study was 719
people, covering 3703 person-years (median follow up 5
years, IQR 3 to 7).
Data collection
Participants attended study visits in outpatient depart-
ments at each centre. Data were collected for age, gen-
der, body mass index (BMI), smoking, symptom
duration (months), serology, DAS28 (erythrocyte sedi-
mentation rate (ESR), swollen joint count (SJC), tender
joint count (TJC), visual analogue scale (VAS) for global
disease, HAQ disability, SF36 quality of life (norm-trans-
formed for Bodily Pain (BP), Vitality (VT) and Mental
Health (MH) subscales) [15].
Flare classification
DAS28 Flare and Pain Flare were derived separately. To
avoid multiple counting, the first DAS28 Flare and the
first Pain Flare after baseline were each selected for ana-
lyses. DAS28 Flares were classified if there was an in-
crease between consecutive study visits in DAS28 ≥ 1.2;
or an increase ≥0.6 if the first of the paired visits had
DAS28 ≤ 3.2 [1, 2]. Pain Flares were classified if there
was a worsening ≥4.8 points of non-normed SF36-BP
between consecutive measurements. This was derived
using the mean increase in SF36 Bodily Pain score asso-
ciated with a 1.2 point increment in DAS28 at baseline.
The linear regression coefficient between DAS28-ESR vs
SF36-Bodily Pain at baseline was − 3.96 (se, 0.23).
Flare severities were measured as change in each vari-
able from the previous time point to the flare event. The
term “before” refers to the single measurement at the as-
sessment immediately preceding the designated flare;
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following. If no data were available at the before or after
time points, then the data were classified as missing.
Statistical analysis
Potential heterogeneity within DAS28 or Pain flares ex-
perience were investigated by Latent Class Analysis (LCA)
of change scores for ESR, SJC, TJC, VAS, SF36-BP, SF36-
VT, SF36-MH to search for flare subgroups. Several char-
acteristics of the LCA models were assessed to provide
guidance for the number of latent classes that were se-
lected [16]. An initial estimate was made for the amount
of information lost by the simplest LCA model. Diagnostic
indices Akaike Information Criteria (AIC), Bayesian infor-
mation Criteria (BIC), sample size adjusted BIC (ssBIC)
were derived for a 1 class model (ie. no subgroups). Then
incremental, iterative increases in the number of classes
were employed [17, 18]. A comparison was made between
increasing numbers of classes for each of the diagnostic
indices (AIC, BIC and ssBIC), plus entropy values, and the
improvement compared to the previous model (assessed
by p values from Vuo-Lo-Mendell-Rubin likelihood ratio
test (VLMR) and Bootstrap likelihood ratio test (BLRT))
[8, 16]. A lower limit of 5% subgroup size was set for
LCA, to give meaningful classes. Each index, test or meas-
urement gave information regarding the preferred model
which best explained and fitted the flare severity data.
Smaller values of AIC, BIC and ssBIC as the number of
classes increased was considered desirable, indicating less
information loss. Entropy (range 0–1) reflected the overallTable 1 Demographics of the eligible population at cohort baseline
Categories or possible rang
n
Sex % Female
Age (y)
Smoking % Current Smoker
% Ex-smoker
Body mass index (kg/m2)
DAS28-ESR
Erythrocyte Sedimentation Rate (mm/h)
Swollen joint count 0–28
Tender joint count 0–28
Visual analogue scale (mm) 0–100
Seropositive
SF36 Bodily Pain 0–100
SF36 Vitality 0–100
SF36 Mental Health 0–100
HAQ 0–3
Baseline demographics at recruitment of participants who were eligible for this ana
Pain (Eligible population) and the subgroups who were classified as experiencing fl
to local laboratory reference ranges. Mean (sd) or percentprobability that cases were assigned to the correct latent
class, and higher values indicate less uncertainty. LMR-
LRT and BLRT were tests for goodness of fit compared to
the previous model, and low p-values indicated a likely
improvement derived from the addition of an extra latent
class. Proposed latent classes were examined for possible
clinical interpretation and were assigned names based
upon their presentation. This process is summarised in
Additional file 2: Table S1.
Heterogeneity between flares and latent classes was
assessed by ANOVA, and by t-tests with Bonferonni cor-
rection. Heterogeneity was sought for characteristics be-
fore, during or after the flare. Statistical analyses were
performed using SPSS version 23 (IBM, USA), or, for
LCA, using Mplus (Muthen and Muthen, Los Angeles,
USA). Data from complete cases were used throughout,
and no data imputation was performed.
Results
DAS28 Flares were identified in 45% and Pain Flares in
52% of participants (Table 1). For participants with con-
current data permitting classification both of DAS28
Flare and Pain Flare, 60% (145/240) of participants at
the time of their first DAS28 Flare did not concurrently
fulfil criteria for a Pain Flare, and 64% (181/284) of par-
ticipants at the time of their first Pain Flare did not con-
currently fulfil criteria for a DAS28 Flare. The
seropositive status of participants were similar in the
overall eligible population and those recorded as having
DAS28 Flares and Pain Flares (Table 1).e Eligible population DAS28 Flare Pain Flare
719 323 377
69% 68% 70%
56 (14) 57 (13) 56 (13)
33% 30% 34%
24% 25% 26%
27.7 (5.4) 27.5 (5.3) 27.8 (5.6)
4.8 (1.5) 4.5 (1.6) 4.6 (1.6)
30 (24) 28 (23) 31 (24)
6 (6) 6 (6) 6 (6)
8 (7) 7 (7) 7 (7)
46 (25) 43 (25) 44 (26)
58% 59% 58%
33 (11) 33 (11) 34 (11)
41 (11) 42 (11) 42 (11)
46 (11) 47 (11) 47 (11)
1.2 (0.9) 1.1 (0.8) 1.1 (0.7)
lysis by having at least 2 consecutive measurements of DAS28 and SF36-Bodily
ares. Seropositive; for rheumatoid factor or anti-citrullinated peptide according
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of recruitment into the ERAN cohort did not differ to
any clinically important extent between those who dis-
played either DAS28 or Pain Flare and the total eligible
population (Table 1). The time to event analysis for first
DAS28 Flare and first Pain Flare is shown on a Kaplan-
Meier plot (Additional file 1: Figure S1). The first Pain
flare occurred sooner than the first DAS28 flare (median
(IQR), 4 (3–5) vs 6 (5–7) years; χ2 = 12.5, p = 0.0004). As
expected, DAS28 Flares were associated with greater in-
creases in DAS28, and in each DAS28 component, thanFig. 1 Characteristics of DAS28 Flares and Pain Flares. Data represent mean
preceding assessment (note different scales in each panel). a DAS28 and P
axis shows worsening change for BP=SF36-Bodily Pain, VT = SF36-Vitality, M
for SJC, TJC and DAS28were Pain Flares; whereas Pain Flares were associated
with greater deteriorations in SF36 Bodily Pain score
(Fig. 1a). Deteriorations in Vitality and Mental Health
scores were similar during DAS28 or Pain Flares.
LCA identified 3 DAS28 Flare subgroups (Fig. 1b,
Table 2). One DAS28 Flare subgroup (which we named
‘Observed DAS28 Flares’, 14% (34/236)) was charac-
terised by greater increases in tender and swollen joint
counts and a second subgroup (‘Self-report DAS28
Flares’, 13% (31/236)) was characterised by greater in-
creases in patient-reported measurements including(95% CI) changes in each outcome at the time of flare compared to
ain Flares; b subgroups of DAS28 Flare; c subgroups of Pain Flare. Y1
H=SF36-Mental Health and VAS-GH. Y2 axis shows worsening change
Table. 2 Characteristics indicated by severity of change during DAS28 Flares
All
DAS28
Flares
(n =
323)
Moderate
DAS28
Flare (n =
171)
Self-
report
DAS28
Flare
(n = 31)
Observed
DAS28
Flare (n =
34)
p Pairwise comparison between DAS28 Flare subgroups (p value)
M vs SR M vs O SR vs O
DAS28 1.7 (0.8) 1.5 (0.7) 2.3 (1.0) 2.3 (0.7) < 0.001 < 0.001 < 0.001 0.999
ESR 9 (15) 11 (16) 13 (17) 7 (12) 0.206 0.999 0.510 0.247
SJC 3 (4) 2 (3) 4 (4) 6 (6) < 0.001 0.011 < 0.001 0.100
TJC 5 (6) 3 (3) 6 (5) 15 (5) < 0.001 < 0.001 < 0.001 < 0.001
VAS 21 (25) 19 (21) 55 (23) 14 (23) < 0.001 < 0.001 0.801 < 0.001
BP 5 (10) 3 (9) 16 (12) 2 (9) < 0.001 < 0.001 0.999 < 0.001
VT 3 (9) 2 (8) 18 (7) −1 (8) < 0.001 < 0.001 0.478 < 0.001
MH 3 (9) 1 (8) 14 (10) 0 (9) < 0.001 < 0.001 0.999 < 0.001
Data are mean (sd) changes at the time of DAS28 Flare categorisation from the preceding assessment. Change during Flare is rescaled to indicate worsening with
positive values for all measures (including SF36 subscales). Significant heterogeneity between latent classes was recorded after univariate ANOVA. Pairwise
comparisons with p values (shown after Bonferonni corrections) were performed. MvSR =Moderate vs Self-report. MvO =Moderate vs Observed. SRvO=Self-report
vs Observed. Bold indicates the values for the most severely affected subgroups when heterogeneity was detected
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS visual analogue scale for general health, BP SF36-Bodily Pain, VT SF36-
Vitality, MH SF36-Mental Health. Changes in SF36 scores = 10 indicate one standard deviation predicted for the UK population
McWilliams et al. BMC Rheumatology            (2019) 3:49 Page 5 of 9VAS-GH and tender joint count (Table 3). One DAS28
Flare subgroup (named ‘Moderate DAS28 Flares’, 72%
(171/236)) displayed less severe deteriorations in out-
come measures than did the other 2 subgroups. 36% of
people with Moderate, and 27% with Observed DAS28
Flares concurrently fulfilled the Pain Flare criterion,
whereas 79% of people with Self-report DAS28 Flares
concurrently fulfilled the Pain Flare criterion. Observed
DAS28 Flares tended to occur on a background of high
pre-flare DAS28, symptoms and disability (Table 2).
Two discrete Pain Flare subgroups were identified by
LCA (Table 4, Fig. 1c) which differed in clinical severity
both before (Table 5 and Fig. 2b, d, f) and during the
flare (Table 4). One Pain Flare subgroup (which weTable. 3 DAS28 Flare subgroups and their characteristics at the visit
Moderate
DAS28
Flare (n =
171)
Self-
report
DAS28
flare
(n = 31)
Observed
DAS28
flare (n =
34)
DAS28 2.6 (1.1) 3.2 (1.3) 4.0 (1.1)
ESR 16 (13) 26 (20) 22 (17)
SJC 1 (2) 1 (3) 3 (4)
TJC 2 (4) 3 (4) 5 (4)
VAS 24 (18) 20 (16) 45 (28)
BP 40 (11) 42 (12) 33 (11)
VT 46 (11) 50 (9) 36 (12)
MH 50 (10) 52 (10) 44 (11)
HAQ 0.8 (0.8) 0.9 (0.8) 1.4 (0.9)
Data are mean (sd) of characteristics at the visit before flare criteria were satisfied. S
categorisation was recorded after univariate ANOVA. Pairwise comparisons with p v
sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS visual analo
Mental Health. SF36 scores 50 indicate predicted population means, with lower scor
Moderate vs Observed. SRvO Self-report vs Observed. Bold indicates the values fornamed ‘Primary Pain Flares’, 11% (43/377)) displayed
large increases in pain following a period of low disease
activity and symptoms. The other Pain Flare subgroup
(which we named ‘Incremental Pain Flares’, 89% (334/
377)) occurred on the background of ongoing active dis-
ease and chronic pain (Table 5 and Fig. 2b, d, f). 77% of
people with Primary Pain Flares but only 30% of people
with Incremental Pain Flares concurrently fulfilled the
DAS28 Flare criterion.
We assessed whether flares were followed by contin-
ued worsening of RA severity (Fig. 2). Both DAS28 and
Bodily Pain scores improved at the next assessment after
the flare event, but not necessarily to the level which
preceded the flare (Fig. 2). Most variables remainedbefore that at which they satisfied flare criteria
p Pairwise comparisons
MvSR MvO SRvO
< 0.001 0.013 < 0.001 0.017
0.001 0.003 0.086 0.965
0.006 0.999 0.004 0.142
< 0.001 0.348 < 0.001 0.196
< 0.001 0.949 < 0.001 < 0.001
0.001 0.999 0.002 0.005
< 0.001 0.113 < 0.001 < 0.001
0.005 0.999 0.009 0.012
< 0.001 0.999 < 0.001 0.030
ignificant heterogeneity between latent classes at the time point before flare
alues (shown after Bonferonni corrections) were performed. ESR erythrocyte
gue scale for general health, BP SF36-Bodily Pain, VT SF36-Vitality, MH SF36-
es indicating greater health impairment. MvSR Moderate vs Self-report, MvO
the most severely affected subgroups when heterogeneity was detected
Table 4 Characteristics indicated by severity of change during Pain Flares
All Pain Flares (n = 377) Incremental Pain Flare (n = 334) Primary Pain Flare (n = 43) p
DAS28 0.6 (1.4) 0.3 (1.1) 1.8 (1.4) < 0.001
ESR 1 (17) 0 (16) 12 (18) < 0.001
SJC 1 (4) 0 (4) 2 (4) 0.012
TJC 1 (5) 1 (5) 4 (6) 0.001
VAS 15 (26) 11 (24) 40 (30) < 0.001
BP 11 (6) 10 (4) 23 (5) < 0.001
VT 4 (9) 4 (9) 9 (10) 0.001
MH 4 (10) 3 (10) 8 (9) 0.005
Data are mean (sd) changes at the time of Pain Flare categorisation from the preceding assessment. Change during flare is rescaled to indicate worsening with
positive values for all measures (including SF36 subscales). Pairwise comparisons between latent classes of Pain Flare analysed by univariate t-tests. Bold indicates
the values for the most severely affected subgroups when heterogeneity was detected
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint count, VAS visual analogue scale for general health, BP SF36-Bodily Pain, VT SF36-
Vitality, MH SF36-Mental Health. Changes in SF36 scores = 10 indicate one standard deviation predicted for the UK population
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DAS28 Flare classification, but returned to pre-flare
levels after Observed DAS28 flares. Average Bodily Pain
scores did not return to pre-flare levels by the next as-
sessment in either Pain Flare subgroup, and DAS28 did
not return to pre-flare levels at the assessment following
Primary Pain Flare classification. HAQ scores remained
increased at the assessment following DAS28 or Pain
Flares of any classification (Fig. 2). There were no signifi-
cant differences observed in seropositive status of the
flare subgroups for DAS28 Flare or Pain Flares.
Discussion
We show flares in RA are common and heterogeneous.
Flares of inflammatory disease activity and of pain often
did not coincide. DAS28 and Pain Flares each comprised
multiple discrete subgroups, characterised by increasesTable 5 Pain Flare subgroups and their characteristics at the
visit before that at which they satisfied flare criteria
Incremental Primary p
Pain Flare (n = 334) Pain Flare (n = 43)
DAS28 3.6 (1.5) 2.8 (1.3) 0.001
ESR 23 (19) 20 (16) 0.583
SJC 3 (4) 1 (3) < 0.001
TJC 5 (6) 2 (3) < 0.001
VAS 30 (23) 20 (19) 0.002
BP 42 (10) 50 (7) < 0.001
VT 46 (11) 49 (13) 0.107
MH 50 (11) 53 (8) 0.134
Data are mean (sd) changes at the time of Pain Flare categorisation from the
preceding assessment. Univariate t-tests for comparing the 2 classes of Pain
flare at the time point before the flare. SF36 scores = 50 indicate predicted
population means, with lower scores indicating greater health impairment.
Bold indicates the values for the most severely affected subgroups when
heterogeneity was detected
ESR erythrocyte sedimentation rate, SJC swollen joint count, TJC tender joint
count, VAS visual analogue scale for general health, BP SF36-Bodily Pain, VT
SF36-Vitality, MH SF36-Mental Healthin self-report symptoms or in observed synovitis, and oc-
curring on different background disease activities or pain
severity. DAS28 and Pain typically improved after flares,
but disability was persistently increased. Flares represent
a substantial burden for people with RA, and might con-
tribute to progressive functional decline. Distinguishing
different flare types should inform personalised
treatment.
RA is a chronic inflammatory disease subject to re-
lapse and remission. We show that RA flares are com-
mon and heterogeneous. Patient characteristics were
similar between those experiencing DAS28 or Pain
Flares, each occurred on a background of similar levels
of acute phase response, and each was accompanied by
similar deteriorations in fatigue, mental health and dis-
ability. Different flare types might therefore have similar
impact and affect any individual with RA. However,
DAS28 and Pain Flare episodes differ in severity of ob-
served synovitis or patient-reported pain during the flare
episode, and often did not coincide. Our findings indi-
cate that DAS28-defined flares alone might not repre-
sent the breadth of flare experience in RA and an
alternative, patient-centred classification of RA Pain
Flare identifies episodes that differ from DAS28 Flares.
We show that DAS28 and Pain Flares can be further
subdivided into discrete classes, further emphasising the
heterogeneous nature of the RA experience.
Different flare types might represent different aspects
of RA pathophysiology. Inflammation causes joint pain,
and RA flares have been defined in terms of increases in
DAS28 [3]. However, RA pain may be due to mecha-
nisms other than inflammation, including central sensi-
tisation or joint damage [19]. Discordance between pain
and signs of inflammation have been noted in previous
cross sectional studies of RA [8, 20, 21]. Our findings in-
dicate that discordance between inflammation and pain
is also characteristic of flare events. Self-report DAS28
Flares resemble the previously described ‘discordant’
Fig. 2 Changes in disease activity, pain and disability scores associated with DAS28 and Pain Flares. Mean (95% CI) of DAS28, SF36-Bodily Pain
and HAQ scores at assessments before, during and after flare categorisation for DAS28 Flares (a, c, e respectively) and Pain Flares (b, d, f
respectively). Statistical significant differences are denoted between during and after (** p < 0.01, * p < 0.05) and between before and after (++
p < 0.01 and + p < 0.05) flare categorisation
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report but relatively low observed disease activity mea-
sures [8]. Such discordance has been associated with
central sensitisation or fibromyalgia [20, 22].
DAS28 and Pain typically improved after flares, but
disability was persistently increased after any type of
flare studied. In the self-report DAS28 Flare subgroup,
DAS28 and Pain also remained persistently increased
after flare, and pain also remained persistently increased
after Pain Flare classification. Flares across different sub-
types therefore can have long term detrimental effects.
Flares can promote also disease progression [6, 23, 24],
and inflammation can lead to central sensitisation [25]
which contributes to persistent pain. Changes in activity,
domestic responsibilities, or employment during flares
might lead to longer term behavioural and functional
changes that contribute to persistent disability.
Patients often present to health care providers during
flares, and treatment aims to both relieve currentsymptoms and prevent long term sequelae. Different strat-
egies might be targeted to prevent or treat different flare
types. Flare treatment often focuses on suppressing inflam-
matory disease, for example by glucocorticoid administra-
tion or DMARD escalation, and this strategy might be
most effective where there is objective evidence of syno-
vitis. RA inflammatory disease may be active and continue
to damage joints even in the absence of notable pain [26].
Non-inflammatory RA pain is associated with less joint
damage [27] and might still be resistant to treatment by
immunosupression or anti-inflammatory drugs [28, 29].
Self-report DAS28 and Primary Pain Flares were also asso-
ciated with worse mental health scores, suggesting that
treatment of psychological comorbidity might be indicated.
Effective disease suppression might reduce flares, but sup-
pression of inflammation alone might not be sufficient to
prevent disability progression. Adjunctive medical, phy-
siotherapeutic or occupational approaches might be neces-
sary to improve outcomes in people who experience flares.
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tions. Flares will have occurred and resolved between as-
sessments in the ERAN cohort, although the per
protocol assessment schedule in ERAN might mean that
flares classified during ERAN assessments were repre-
sentative of RA flares. Assessments might not have cap-
tured data at a flare’s peak, and pre-flare data might not
reflect the patient’s best clinical status. Our data there-
fore are likely to underestimate the prevalence of flares
in this RA population. Our definitions of flare have evi-
dence of validity [2], but we do not know whether pa-
tients or physicians considered participants to be in flare
at the time of our flare classification. Our criterion for
Pain Flares was validated against OMERACT flare classi-
fication and concurs with Minimal Clinically Important
Differences in pain [30]. Pain Flares were not validated
directly against patient self-reported flare, but displayed
similar overall severity to DAS28 Flares. Identification of
flare subgroups depends upon the variables entered into
latent class models, and it is possible that additional het-
erogeneity exists within our identified flare subgroups.
For example, fatigue behaved similarly between our flare
subgroups, although flares of fatigue might also display
discrete subgroups [7]. It is also possible that non-
random patterns of missing data might have influenced
the study findings. There were more missing data in
analyses of DAS28 Flares than in Pain Flares. One of the
contributing reasons was that some people had data for
DAS28 recorded but without the 4 components. DAS28
Flare classification incorporates components measuring
both symptoms and signs of inflammation [31, 32].
More objective measures of synovitis such as ultrasound
imaging might reveal greater separation between inflam-
matory and pain flare subtypes. It is also possible the
omission of the VAS from the DAS28 might also show
more separation of inflammatory and pain flare sub-
types. Measurement error might have contributed to
some flare classifications, although the magnitudes of
change that were recorded are regarded as clinically im-
portant. We have also not been able to analyse how
DMARD medication choices might control or contribute
to flares, and future randomised controlled trials might
usefully explore flare reduction as a clinically relevant
outcome of treatment.
Conclusion
In conclusion, we show that flares in RA are common
and heterogeneous. DAS28 and Pain Flares are discrete
entities indicative of differing underlying mechanisms,
but both have immediate patient impact and lead to lon-
ger term disability. Identifying and understanding RA
flare subgroups should guide treatment. Due to their
intermittent nature, flares might go unnoticed between
regular reviews, but represent a substantial burden forpeople with RA, and might contribute to progressive
functional decline. Treatments are needed to reduce
flare incidence as well as supressing flares when they
happen, and should aim to reduce long term disability
and pain, as well as improving current symptoms.Supplementary information
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